Emergent BioSolutions Inc. (EBS)

NYSE • Healthcare

$6.23

+$0.03 (+0.5%)

Market closed

Last close at October 22, 2026 at 20:00 UTC

Open$6.17

Day Range$6.08 - $6.36

Avg. Volume (3M)1M

Market Cap$318.1M

52 Week Range

$4.36$14.06

Next EarningsIn 11 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$234.3M100%

Gross Profitminus cost of goods$137.2M59%

In plain terms: out of every $100 in revenue, Emergent BioSolutions Inc. currently loses $77.

Fundamentals & Financials

Revenue (TTM)

$770.2M

Net Income (TTM)

-$176.8M

EPS (TTM)

-$3.44

ROA (TTM)

-15.83%

Current Ratio

5.42

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+161.5%Q3 2025$0.16

+983.3%Q4 2025$1.06

-490.9%Q1 2026-$0.43

+184.0%Q2 2026$0.21

+805.9%Q3 2026$0.6

Nov 2

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +805.9%

Emergent BioSolutions beat expectations on both the top and bottom line in preliminary second fiscal quarter of 2026 results reported Aug. 5, as revenue rose about 66% to about $234.3 million from about $140.9 million a year ago and topped the $177.5 million estimate by 32.0%. Adjusted EPS of $0.60 beat the -$0.09 estimate by 805.9% and was up 275% from $0.16 a year ago, while gross profit reached roughly $137.2 million and gross margin held near 59%. MCM Product sales led at about $168.0 million, up 188%, alongside USG at about $157.1 million, up 172%, while Commercial Product sales fell 22% to about $52.4 million. Operating cash flow was negative about $16.2 million, the company repurchased about $8.8 million of stock, and next-period consensus calls for EPS of $0.14 on revenue of $209.0 million.

Next report — what to expect

Emergent BioSolutions Inc. (EBS) reports on November 4, 2026. Wall Street is looking for consensus EPS of -$0.37 on revenue of $123.2 million. For trailing context, revenue rose +66.3% year over year last quarter. EBS has beaten EPS in 7 of 8 most recent quarters, making any variance from expectations a key focus.

View full earnings history

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. develops and supplies biodefense and public-health countermeasures in the healthcare and biotechnology field. Listed on the NYSE as EBS, it sells vaccines, therapeutics, medical countermeasures, and manufacturing services centered on U.S. government and health-security demand, and generated $742.9 million of revenue in FY2025.

Name

Emergent BioSolutions Inc.

CEO

Joseph C. Papa Jr.

Website

www.emergentbiosolutions.com

Industry

Healthcare

Year Founded

1998

Employees

900

Today's Snapshot

AI-generated

The day ended with EBS 0.6% higher at 6.23, in line with a firmer sector. EBS reports earnings on 2 November.

Trading Volume

Below 10d avg (972.6K)

838.3K

vs S&P 500 Today

Outperforming Market

+1.82%

Updated: October 22, 2026 at 20:20 UTC

Technical Indicators

1 Buy1 Neutral6 Sell

EBS exhibits a bearish technical stance as the price sits under most short- and medium-term averages and well below the 200-day level, while ADX near 17 signals little directional conviction. Momentum indicators skew negative with CCI deeply oversold and MACD slightly negative, and RSI remains below neutral. Volatility is elevated with ATR about $0.39 (a large percentage of the share price), and volume trends are unfavorable given a strongly negative OBV. The pivot is almost at the market and offers little support. Technical takeaway: Sell—the setup shows weakness across momentum and volume with limited trend strength.

All signals